drugset / Trial / NCT00270140

A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Facilitating the Presurgical Collection of Blood to be Used for Self-donation During Surgery on the Spine, Hip, or Knee.

NCT00270140

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety and effectiveness of epoetin alfa at doses of 150, 300, or 600 units per kilogram of body weight versus placebo in facilitating presurgical collection of blood for self-donation during surgery of the knee, hip or spine. Epoetin alfa is a genetically engineered protein that stimulates red blood cell production.

Timeline

Start
1989-09
Primary completion
Completion
1991-08

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic 150 iu/kg Intravenous
Subject epoetin alfa Protein / enzyme biologic 300 iu/kg Intravenous
Subject epoetin alfa Protein / enzyme biologic 600 iu/kg Intravenous

Indications